Thomas Christoph, PhD
Pharmacologist

Qualification

2009
Board Certified Pharmacologist, German Society for Pharmacology and Toxicology (DGPT)
1993
PhD in Immunology (B-lymphocyte development), University of Cologne, Germany
1989
Diploma in Biology (Molecular Biology, Immunology), University of Cologne, Germany

Career History

  • since 2018
    Independent Consultant Translational R&D

    Strategic consulting on translational pharmacology, drug discovery and development and environmental risk assessments for Start-ups, Biotechs and Pharma. External project lead and management for clinical candidates. NIH Heal Initiative, invited panelist at Virtual Meeting Rockville 2020 on “Target Validation for Non-Addictive Therapeutics Development for Pain”, Alexandria 2019 – invited ad-hoc reviewer for Grant No. NIH-NINDS-75N95019R00027 “Screening of Investigational Agents through the NINDS Preclinical Screening Platform for Pain (PSPP)”, Bethesda 2019 – invited participant for conference “Assessment of animal pain models for therapeutics development”. Invitation to serve as mentor at KDDF’s 2020 “Young BD Person Workshop”, Seoul 2020. Regular lectures on “Translational Pain Research” and “Drug Development and Marketing Authorization” at Aachen University since 2020 (RWTH Excellence Cluster).

  • 2022 – 2024
    Chief Development Officer NEUWAY Pharma GmbH

    NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).

  • 2018 – 2020
    Grünenthal, International Preclinical Project Lead

    Preclinical project management of late-stage projects (GLP-phase, sNDA submission). Preclinical support of PSUR/PBRER and DSUR for PV. Preclinical expert reports for regulatory submissions including environmental risk assessments.

  • 2011 – 2018
    Grünenthal, Head Pharmacology

    Budget and staff responsibility for up to 30 FTEs; Pharmacological support to research, development, regulatory, marketing, sales and patent departments; Development and implementation of new translational strategies; International network in industrial contract research and academic research.

  • 1996 – 2011
    Grünenthal, Lab Head Pharmacology

    Project lead on several research (LO phase) and development (phase II) projects. Management of international research co-operations. Development of novel models of pain, inflammation, and bladder function.

  • 1993 – 1996
    Hafslund Nycomed, Research Scientist Pharmacology

    Development of in vitro and in vivo models of pain and inflammation; participation in research projects on pain, inflammation, bladder function, and hair growth.

Publications